drugset / Trial / NCT00992160

Vestipitant 28-day Tolerance Study

NCT00992160

Phase 2 Completed 161 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is a 28-day polysomnographic and subjective assessment of oral Vestipitant 15mg/day for treatment of Primary Insomnia in adults outpatients.

Timeline

Start
2009-05
Primary completion
2009-09
Completion
2009-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Vestipitant Small molecule 15 mg Oral

Indications